In short
Clinical trials are investigating TTX-381 in people with ocular manifestations of CLN2 disease. These studies are designed to assess safety, tolerability, and early signs of benefit in a small group of participants. The current trial focuses on subretinal use in a Phase 1/2 study.
Key points
- TTX-381 is being studied in a small early-phase trial for people with ocular manifestations of CLN2 disease. The study is a Phase 1/2 interventional trial and is currently authorised. It plans to enroll 22 participants. The main goal is to assess safety and tolerability, including ocular and overall adverse events and serious adverse events. The study follows participants through Day 360 to track these outcomes over time.
Trial overview
The available study of TTX-381 is an interventional clinical trial in participants with ocular manifestations of Neuronal Ceroid Lipofuscinosis type 2, also called CLN2 disease. The trial is authorised and plans to enroll 22 participants.
This study is focused on the eye-related signs of the disease and uses subretinal use of TTX-381. Subretinal use means the treatment is given under the retina, which is the light-sensitive layer at the back of the eye.
Who can participate
The trial is designed for people who have ocular manifestations of CLN2 disease. In simple terms, this means the study is for patients whose disease affects the eyes.
No other participant groups are listed in the source data, so the trial population is narrowly defined.
Study design and phase
This is a Phase 1/2 study, which is an early stage of clinical research. Phase 1 studies mainly look at safety, while Phase 2 studies also begin to look for early signs that a treatment may help.
The trial brief summary says it aims to evaluate the safety and tolerability of TTX-381 through Day 360 in participants with CLN2 disease.
What the study measures
The primary outcome is ocular and overall adverse events and serious adverse events through Day 360. Adverse events are unwanted medical problems that happen during the study, and serious adverse events are more severe problems that may need urgent care or hospital treatment.
Because this is an early trial, the main focus is on safety and tolerability rather than proving long-term benefit. The follow-up through Day 360 shows that the study is watching participants over a long period after treatment.
Why this trial matters
CLN2 disease is a rare condition, and this study looks at a targeted group of patients with eye involvement. For patients and families, early trials like this are important because they help researchers learn whether a new approach can be studied safely before larger trials are done.
At this stage, the trial data do not report results, so the main information available is about the study plan, the patient group, and the safety outcomes being tracked.